Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 2/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521457 | 1.00 | P2RY12 (0.59) | P2RY12TDP1NAPEPLDUSP2HPGD | |
| SCHEMBL3059830 | 1.00 | P2RY12 (0.59) | P2RY12TDP1NAPEPLDUSP2HPGD | |
| SCHEMBL29521263 | 0.99 | P2RY12 (0.58) | P2RY12TDP1NAPEPLDUSP2HPGD | |
| SCHEMBL2928595 | 0.91 | P2RY12 (0.53) | P2RY12TDP1NAPEPLDUSP2HPGD | |
| SCHEMBL3044404 | 0.91 | P2RY12 (0.53) | P2RY12TDP1NAPEPLDUSP2HPGD | |
| SCHEMBL29510604 | 0.90 | P2RY12 (0.56) | P2RY12TDP1NAPEPLDUSP2HPGD | |
| SCHEMBL3051255 | 0.90 | FPR2 (0.52) | P2RY12NAPEPLDLMNATTRRBP4 | |
| SCHEMBL3051259 | 0.90 | FPR2 (0.52) | P2RY12NAPEPLDLMNATTRRBP4 | |
| SCHEMBL3062233 | 0.90 | P2RY12 (0.50) | P2RY12TDP1NAPEPLDLMNATTR | |
| SCHEMBL3062229 | 0.90 | P2RY12 (0.50) | P2RY12TDP1NAPEPLDLMNATTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163086-A1 | Crystalline Forms | VIATRIS ASIA PACIFIC PTE LTD (SG) | 2025-05-22 | — | — | US | disclosed |
| US-12227532-B2 | Crystalline forms | Viatris Asia Pacific Ptd. Ltd. (SG) | 2025-02-18 | — | — | US | disclosed |
| US-20220275011-A1 | CRYSTALLINE FORMS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2022-09-01 | — | — | US | disclosed |
| US-11365209-B2 | Crystalline forms | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-21 | — | — | US | disclosed |
| CN-109715639-B | Crystalline forms | 爱杜西亚药品有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3981774-A1 | CRYSTALLINE FORMS | Idorsia Pharmaceuticals Ltd (CH) | 2022-04-13 | — | — | EP | disclosed |
| EP-3515924-B1 | CRYSTALLINE FORMS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-11179390-B2 | Subcutaneous administration of a P2Y12 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-23 | — | — | US | disclosed |
| US-20210009614-A1 | CRYSTALLINE FORMS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-01-14 | — | — | US | disclosed |
| US-10730896-B2 | Crystalline forms | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-08-04 | — | — | US | disclosed |
| US-20200129510-A1 | SUBCUTANEOUS ADMINISTRATION OF A P2Y12 RECEPTOR ANTAGONIST | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2020-04-30 | — | — | US | disclosed |
| EP-3595666-A1 | SUBCUTANEOUS ADMINISTRATION OF A P2Y12 RECEPTOR ANTAGONIST | Idorsia Pharmaceuticals Ltd (CH) | 2020-01-22 | — | — | EP | disclosed |
| EP-3515924-A1 | CRYSTALLINE FORMS | Idorsia Pharmaceuticals Ltd (CH) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018167139-A1 | SUBCUTANEOUS ADMINISTRATION OF A P2Y12 RECEPTOR ANTAGONIST | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-20 | — | — | WO | disclosed |
| WO-2018055016-A1 | CRYSTALLINE FORMS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-29 | — | — | WO | disclosed |
| US-8518912-B2 | Phosphonic acid derivates and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2225253-B1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-10-14 | — | — | US | disclosed |
| EP-2225253-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009069100-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY13, P2RY11 | P2RY12 1/4885TDP1 1192/4885NAPEPLD 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.